Saol Therapeutics develops experimental medicines for rare metabolic and neurological conditions. Its lead candidate, SL1009, is an oral sodium dichloroacetate treatment that, if approved, would be used with a genetic test to determine dosing for children with pyruvate dehydrogenase complex deficiency. The privately held company has secured an Oaktree credit facility of up to $115 million to prepare for a possible launch; the transaction closed Sept. 11, while the drug remains under FDA review.
The proposed workflow combines the medicine with a required companion test. The test identifies a patient’s GSTZ1 genotype and classifies the person as a fast or slow drug metabolizer, informing an individualized dose of the oral solution. Saol says that dose selection is intended to reduce adverse events such as peripheral neuropathy. SL1009 remains investigational and is not approved for any indication.
Saol describes PDCD as a mitochondrial disorder that disrupts carbohydrate oxidation, reducing energy production and potentially causing lactic acidosis, developmental problems and early childhood death. The company’s stated rationale is that sodium dichloroacetate inhibits pyruvate dehydrogenase kinases, with the aim of stimulating residual enzyme activity and increasing mitochondrial ATP production. The required dosing test makes the prospective product a medicine-and-diagnostic package rather than a stand-alone drug.
Saol first submitted SL1009 for approval in 2024 and received a complete response letter from the FDA in August 2025. After providing additional survival analyses, it resubmitted the application in June 2026. The FDA accepted the filing as a Class 2 response and set Dec. 30 as its target action date, placing the candidate in a second review cycle rather than indicating that approval is assured.
The facility provides up to $115 million in milestone-based capital. An initial tranche is designated for near-term launch readiness, while the rest depends on regulatory, clinical and commercial milestones. Saol says later capital could also support SL1009 development for congenital lactic acidosis and expand its injectable SL1002 candidate into additional pain and spasticity indications.
The financing allows Saol to build a commercial organization while the regulatory review remains pending, but the product requires coordination beyond the drug application. Saol and collaborator Medosome Biotec say they plan to file a 510(k) submission for the dose-determining test. The business question is whether they can bring the medicine and required companion test through their respective reviews and have both ready on the same commercial timetable.